BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial

  After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed greater improvements after 96 weeks of treatment in an advanced disease population.

  January 27, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  IPO

  Metsera Seeks $289M Raise, $1.78B Valuation in IPO

  The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

  January 27, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• Press Releases

  Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

  January 27, 2025

   · 

  19 min read
• Press Releases

  Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

  January 27, 2025

   · 

  5 min read
• Press Releases

  Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

  January 27, 2025

   · 

  19 min read
• Press Releases

  FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

  January 27, 2025

   · 

  22 min read
• Press Releases

  Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA

  January 27, 2025

   · 

  6 min read
• Press Releases

  CStone Partners with SteinCares to Market Sugemalimab in Latin America

  January 27, 2025

   · 

  6 min read
• Press Releases

  Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

  January 27, 2025

   · 

  14 min read
• Press Releases

  bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types

  January 27, 2025

   · 

  5 min read